ACE2 targeting COVID-19 vaccine prototype (recombinant BC-PIV/VLP/BC-PIV viral vector) (Mie University/BioComo/MediciNova)

N/A

Report date: 2025/01/26 15:16:39

Base Information

Drug NameACE2 targeting COVID-19 vaccine prototype (recombinant BC-PIV/VLP/BC-PIV viral vector) (Mie University/BioComo/MediciNova)
Drug Alias Namerecombinant BC-PIV viral vector vaccine(Mie University/BioComo/MediciNova)BC-PIV COVID-19 vaccine (Mie University/BioComo/MediciNova)
ClassificationVaccines > Application > Prophylactic vaccineBiologics > Protein drugs > Recombinant proteinVaccines > Development/production technology > Inactivated vaccine > Subunit vaccine +[4] 
Mechanisms of ActionAngiotensin-converting enzyme 2 modulatorsCoronavirus spike glycoprotein modulators
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesJapan
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMie University
China Registration ClassN/A

Develop Information

Active CompaniesMie UniversityMedicinova IncBioComo Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A